NY-MSCI
10.6.2024 14:01:27 CEST | Business Wire | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today launched MSCI AI Portfolio Insights. Combining generative artificial intelligence (“GenAI”) with MSCI’s award-winning analytics tools and advanced modelling technologies, MSCI AI Portfolio Insights is designed to help investors better identify and manage potential emerging risks that dynamic markets pose to their portfolios.
MSCI has combined its extensive risk and performance modelling capabilities with GenAI to enhance risk reporting. MSCI AI Portfolio Insights aims to create efficiencies and deliver insights to institutional risk and portfolio managers by helping identify and analyze the most salient information in risk reports before the working day starts.
Investors can use MSCI AI Portfolio Insights’ interactive capabilities to drill further into changes in their portfolios without any need for code or extensive user interface dropdowns. MSCI AI Portfolio Insights merges generated text with modern dashboards and cloud-based technology to enhance communication and efficiency in risk and portfolio management. These tools aim to empower risk management teams at asset managers, hedge funds and asset owners to drive collaboration across their firm's investment teams.
Traditionally, risk managers have invested significant time and resources integrating complex models to process, clean, generate, store, and extract all data necessary to provide a comprehensive overview of risk and performance. Today, risk leaders at investment firms face increased pressure to deliver both enterprise-wide risk monitoring on a growing number of portfolios and risk advisory services to their investment teams. At the same time, global challenges like climate change, geopolitical tensions, macroeconomic uncertainty, and technological advancements have created new investment challenges and opportunities for risk leaders to monitor.
MSCI AI Portfolio Insights leverages proprietary algorithms to curate large volumes of data, aiming to surface the most important factors impacting risk and performance and connecting them as appropriate to market events. It also features an AI agent to help risk managers further understand and decompose the risk and performance drivers. Based on natural language interaction, the assistant can answer complex questions about portfolios.
“Institutional investors both can and must shift their risk teams from being largely control-oriented to also being an investment-focused function,” said Ashley Lester, Chief Research Officer at MSCI. “With MSCI AI Portfolio Insights, we are transforming risk reporting to make it more insightful and more accessible to investment decision makers. Risk should not be just about monitoring: it should be about providing investors with actionable insights.”
MSCI also introduced the Macro Finance Analyzer today, leveraging MSCI’s financial modeling and stress-testing capabilities. This tool is designed to test how changes to macroeconomic conditions could affect a portfolio’s risks and returns across asset classes, supporting investors’ asset allocation decisions. Users can explore and test a wide variety of conditions, with the ability to adjust expectations for rapidly evolving market events and trends – like potential impacts of interest rate changes or changes in long-term economic growth.
“At MSCI, we have observed a shift in the relationship between investment and risk management teams, driven by senior investment leaders’ growing demand for the integration of risk analytics into the investment process,” said Jorge Mina, Head of Analytics at MSCI. “Risk teams must seek efficiencies, modernize processes, and enhance the guidance they offer to the entire investment organization. To accomplish these goals and increase collaboration with portfolio managers, risk managers need the right toolkit, which is now provided on a single platform by MSCI.”
MSCI’s portfolio analytics tools are available on MSCI ONE, a cloud-based technology platform that combines flexible distribution, cloud delivery, dashboards, and visualizations. Launched in 2022, the platform enables users to seamlessly navigate MSCI’s robust analytics to help them identify key insights, innovate rapidly, and build investment portfolios that seek to deliver better strategic outcomes.
-Ends-
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610715107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom